Introduction
============

Pancreatic cancer is one of the most aggressive human malignancies worldwide. Despite improvements in surgical and chemotherapeutic approaches over the past decades, the prognosis of pancreatic cancer remains dismal; the average overall 5-year survival rate is \<5%.[@b1-ott-8-1651] The reasons for this are the challenges associated with diagnosis, which tends to be late and uncertain; more importantly, therapeutic options are limited. Even with early diagnosis and surgical resection with curative intention, nearly all patients develop local recurrence or distant metastases following surgery and eventually succumb to the debilitating effects of metastatic growth.[@b2-ott-8-1651],[@b3-ott-8-1651] Conventional chemotherapy is rarely curative for metastatic pancreatic cancer. In recent years, there have been important advances in the organization of care for patients with pancreatic cancer; these advances have also resulted in more focused studies on surgical, oncological, and immunological treatment.

The Wnt/β-catenin pathway is a genetically conserved signaling pathway associated with a variety of human conditions such as birth defects and tumors. Abnormal Wnt/β-catenin pathway activation is closely related to the development of many cancers.[@b4-ott-8-1651],[@b5-ott-8-1651] An increasing amount of evidence demonstrates that both the β-catenin-dependent (canonical) and β-catenin-independent (non-canonical) Wnt signaling pathways play a key role in regulating pathological processes by facilitating tumor growth, migration, and invasion. In canonical Wnt signaling, glycogen synthase kinase-3β (GSK-3β) phosphorylates β-catenin at certain key residues, leading to its ubiquitination and subsequent degradation.[@b5-ott-8-1651],[@b6-ott-8-1651] Non-phosphorylated β-catenin accumulates in the cytoplasm, and pathway activation leads to nuclear accumulation of β-catenin and interaction with T-cell factor (TCF) transcription factors, subsequently stimulating the downstream target genes, which include the genes participating in cell metastasis and proliferation.[@b7-ott-8-1651],[@b8-ott-8-1651]

Abnormal Wnt/β-catenin pathway activation plays an important role in human pancreatic cancer, where it causes extracellular matrix degradation and uncontrolled cell proliferation and differentiation.[@b9-ott-8-1651] Recent studies have demonstrated that FH535 is a synthetic inhibitor of the canonical Wnt signaling pathway; it inhibits the growth of colon, lung, breast, and hepatocellular carcinoma lines,[@b10-ott-8-1651],[@b11-ott-8-1651] suggesting that small-molecule targeting of the Wnt/β-catenin pathway could be a promising therapeutic approach for cancers in which this pathway is activated.

In this study, we investigated the anti-cancer effect of FH535 on pancreatic cancer and explored the mechanisms underlying the effect, providing a rationale for further development of FH535 as a promising therapeutic agent for treating pancreatic cancer.

Materials and methods
=====================

Cell cultures and reagents
--------------------------

The human pancreatic cancer cell lines PANC-1 and BxPC-3 were purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 μg/mL streptomycin (Thermo Fisher Scientific) at 37°C in a 5% CO~2~ incubator under a humidified atmosphere; the cells were passaged every 2--3 days for exponential growth. FH535 was purchased from EMD Millipore (Billerica, MA, USA).

Western blotting
----------------

Total protein was extracted using a lysis buffer (50 mM Tris-HCl \[pH 7.4\], 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate \[SDS\], 1 mM EDTA) supplemented with a protease inhibitor cocktail kit and a phosphatase inhibitor cocktail kit (Hoffman-La Roche Ltd., Basel, Switzerland). The protein extracts were loaded, size-fractionated by SDS-polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA). After blocking, the membranes were incubated with the primary antibodies mouse anti-β-catenin (Santa Cruz Biotechnology Inc., Dallas, TX, USA) and rabbit anti-β-actin (Proteintech Group Inc., Chicago, IL, USA) at 4°C overnight. Protein expression was determined using horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies, followed by detection using enhanced chemiluminescence (EMD Millipore). Band intensity was visualized using a JS-1035 image analysis scanning system (Shanghai Peiqing Science & Technology, Co., Ltd., Shanghai, People's Republic of China).

Luciferase reporter assay
-------------------------

β-catenin is a dominant factor in the Wnt/β-catenin/TCF signaling pathway, which regulates gene transcription by binding β-catenin and TCF. The activity of this final step in the pathway can be precisely measured using a luciferase reporter construct. The reporter plasmid pTOPFLASH (TCF reporter plasmid; EMD Millipore) contains two sets (the second set is in the reverse orientation) of three copies of the TCF binding site (wild-type) upstream of the thymidine kinase minimal promoter and luciferase open reading frame. The internal control plasmid pRL-SV40 (Promega Corporation, Fitchburg, WI, USA) contains the *Renilla* luciferase gene. Cells were transiently cotransfected with pTOPFLASH plasmid (500 ng/well) and pRL-SV40 plasmid (100 ng/well) for 6 hours using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol. Then, the medium was renewed and FH535 was added. After 24 hours of treatment, cell lysates were subjected to the dual luciferase reporter assay according to the manufacturer's recommendations; luciferase activity was measured using a luminometer (Turner Designs, Sunnyvale, CA, USA). The results are expressed as relative luciferase activity, ie, the ratio of firefly luciferase activity over *Renilla* luciferase activity.

Wound healing assay
-------------------

Cells (1×10^4^/well) were seeded in 96-well plates and grown to confluence. The monolayer culture was artificially scrape wounded with a sterile micropipette tip to create a denuded zone of constant width. Each well was washed with phosphate-buffered saline twice to remove the detached cells before FH535 treatment. Cell migration to the wounded region was observed using an XDS-1B inverted microscope (MIC Optical and Electrical Instrument, Chongqing, People's Republic of China) and photographed (×40 magnification). Images were captured at 0, 8, and 12 hours to monitor the wound healing process. The wound areas were measured using ImageJ (NIH, Bethesda, MA, USA).

Transwell invasion assay
------------------------

We used a 24-well Transwell plate with an 8 μm pore size polycarbonate filter membrane (Corning Incorporated, Corning, NY, USA). Cells (1×10^5^) in 100 μL serum-free DMEM were added to the Matrigel-coated top chamber (BD Biosciences, San Jose, CA, USA); the bottom chamber contained DMEM with 10% FCS. The cells were incubated for 24 hours; cells that had invaded through the Matrigel-coated membrane were fixed and stained with crystal violet and counted under a light microscope in five random fields in a blinded fashion.

Adhesion assay
--------------

Cells were resuspended in complete medium and seeded in 24-well plates at 1×10^4^ cells/mL. After 5-hour incubation, the unattached cells were removed to another well. The attached and unattached cells were evaluated using the 3-\[4,5-dimethylthiazol-2-yl\] 2,5-diphenyltetrazolium bromide (MTT) assay. The adhesion rate was calculated as follows: (absorbance of attached cells/\[absorbance of attached cells + absorbance of unattached cells\]) ×100%.

MTT assay
---------

Cell growth was evaluated using the MTT assay. Cells (5×10^4^/well) were seeded in 24-well tissue culture plates. Blank control was treated with DMSO. After FH535 treatment, MTT (Sigma-Aldrich Co., St Louis, MO, USA) was added to each well (final concentration, 0.5 mg/mL), followed by 4-hour incubation at 37°C. The medium was removed, and 800 μL of dimethyl sulfoxide was added to each well. The absorbance of the mixture was measured at 490 nm using a microplate enzyme-linked immunosorbent assay reader (Bio-Rad Laboratories Inc.). The relative cell viability was calculated as follows: relative cell viability = (mean experimental absorbance/mean control absorbance) ×100%.

Plate clone formation assay
---------------------------

Cells (200/well) were seeded in 24-well plates and treated after 12 hours. After 15 days, the cells were stained with 1% methylrosanilinium chloride, and the number of visible colonies was counted. The relative clone formation ability was calculated as follows: (mean experimental clone number/mean control clone number) ×100%.

Cell cycle analysis
-------------------

Before treatment, the cells were serum starved for 24 hours to synchronize the cell cycle. Then, FCS was added to the cells, followed by various concentrations of FH535. Following 24 hours of FH535 treatment, the cells were fixed in 80% cooled ethanol and incubated with 0.5% Triton X-100 solution containing 1 mg/mL RNase A at 37°C for 30 minutes. Next, propidium iodide (Sigma-Aldrich Co.) was added to the wells (final concentration, 50 μg/mL), followed by 30-minute incubation in the dark. Cellular DNA content was analyzed using a fluorescence-activated cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA). Data were processed using ModFit LT software (Verity Software House, Topsham, ME, USA).

Microarray assay
----------------

Sample preparation and processing were performed as described in the GeneChip Expression Analysis Manual (Agilent Technologies, Santa Clara, CA, USA). Differentially expressed genes were screened using Agilent 44K human whole-genome oligonucleotide microarrays. The selection criterion was greater than twofold difference in expression (difference in upregulated expression was greater than twofold; difference in downregulated expression was less than 0.5-fold). Hierarchical clustering of samples was performed using an average linkage algorithm using TIGR MultiExperiment Viewer (The Institute for Genomic Research, Rockville, MD, USA).

Statistical analysis
--------------------

Each experiment was performed in at least triplicate. Results are expressed as the mean ± standard deviation. Statistical analysis was performed using an unpaired Student's *t*-test. *P*\<0.05 was considered significant.

Results
=======

FH535 inhibited the β-catenin pathway in pancreatic cancer cells
----------------------------------------------------------------

Treatment with 20 μM FH535[@b12-ott-8-1651] did not affect nuclear or total β-catenin expression in the BxPC-3 cells, but downregulated nuclear and total β-catenin in the PANC-1 cells ([Figure 1A](#f1-ott-8-1651){ref-type="fig"}). The luciferase reporter assay confirmed that FH535 suppressed TCF-dependent transcription, which may have led to dysregulation of the genes downstream of the β-catenin pathway ([Figure 1B](#f1-ott-8-1651){ref-type="fig"}). To verify this, we performed microarray analyses to determine the mRNA expression changes in 138 genes downstream of the β-catenin pathway using Agilent 44K human whole-genome oligonucleotide microarrays (<http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes>); 20 μM FH535 upregulated or downregulated multiple genes ([Figure 1C](#f1-ott-8-1651){ref-type="fig"}, [Table 1](#t1-ott-8-1651){ref-type="table"}).

FH535 inhibited pancreatic cancer cell migration
------------------------------------------------

In all, 20 μM FH535 inhibited pancreatic cancer cell migration in a time-dependent manner ([Figure 2A](#f2-ott-8-1651){ref-type="fig"}). To investigate the mechanisms involved, we analyzed the microarray data to illustrate the expression of genes participating in focal adhesion ([Figure 2B](#f2-ott-8-1651){ref-type="fig"}, [Table 2](#t2-ott-8-1651){ref-type="table"}),[@b13-ott-8-1651],[@b14-ott-8-1651] adhesion junctions ([Figure 2C](#f2-ott-8-1651){ref-type="fig"}, [Table 3](#t3-ott-8-1651){ref-type="table"}),[@b15-ott-8-1651]--[@b17-ott-8-1651] tight junctions ([Figure 2D](#f2-ott-8-1651){ref-type="fig"}, [Table 4](#t4-ott-8-1651){ref-type="table"}),[@b18-ott-8-1651]--[@b23-ott-8-1651] and cell motility ([Figure 2E](#f2-ott-8-1651){ref-type="fig"}, [Table 5](#t5-ott-8-1651){ref-type="table"}).[@b24-ott-8-1651]--[@b27-ott-8-1651]

FH535 inhibited pancreatic cancer cell invasion
-----------------------------------------------

The Matrigel invasion assay revealed that FH535-treated cells had significantly decreased invasive capacity as compared with the control cells ([Figure 3A](#f3-ott-8-1651){ref-type="fig"}), supporting the premise that FH535 inhibits pancreatic cancer cell invasion. Moreover, FH535 inhibited the adhesion ability of pancreatic cancer cells dose-dependently ([Figure 3C](#f3-ott-8-1651){ref-type="fig"}). We also analyzed the microarray data to explore the changes in the expression of genes involved in the in vitro invasion process, including extracellular matrix degradation ([Figure 3B](#f3-ott-8-1651){ref-type="fig"}, [Table 6](#t6-ott-8-1651){ref-type="table"}), cell adhesion ([Figure 3D](#f3-ott-8-1651){ref-type="fig"}, [Table 7](#t7-ott-8-1651){ref-type="table"}),[@b28-ott-8-1651],[@b29-ott-8-1651] and epithelial--mesenchymal transition (EMT) ([Figure 3E](#f3-ott-8-1651){ref-type="fig"}, [Table 8](#t8-ott-8-1651){ref-type="table"}).[@b30-ott-8-1651]--[@b33-ott-8-1651]

FH535 inhibited pancreatic cancer cell growth
---------------------------------------------

Using MTT assay, we evaluated the inhibitory effect of FH535 on pancreatic cancer cell line growth. The proliferation of PANC-1 and BxPC-3 cells cultured for up to 48 hours with FH535 was significantly inhibited time-dependently and dose-dependently as compared to the control cells ([Figure 4A](#f4-ott-8-1651){ref-type="fig"}). The clone formation assays confirmed the dose-dependent inhibitory effect of FH535 on pancreatic cancer cell growth ([Figure 4B](#f4-ott-8-1651){ref-type="fig"}). We performed cell cycle analysis to confirm the antimitogenic effect of FH535. FH535 induced G2/M accumulation and decreased the cell population in the G0/G1 and S phases dose-dependently ([Figure 4C](#f4-ott-8-1651){ref-type="fig"}). The expression profile of the cell cycle--related genes obtained from microarray analyses was analyzed ([Figure 4D](#f4-ott-8-1651){ref-type="fig"}, [Table 9](#t9-ott-8-1651){ref-type="table"}).[@b34-ott-8-1651]

Discussion
==========

It is widely acknowledged that the prognosis of pancreatic cancer is very poor. The canonical Wnt/β-catenin signaling pathway plays a key role in tumor development and dissemination. Classical Wnt signaling pathway causes accumulation of β-catenin in cytoplasm in complex with the transcription factor TCF/LEF that regulates target gene expression.[@b9-ott-8-1651],[@b35-ott-8-1651] Dysregulation of Wnt/β-catenin signaling and altered transcription of β-catenin/TCF-regulated genes are found in many cancers,[@b36-ott-8-1651] including pancreatic cancer.[@b37-ott-8-1651] In this regard, we focused on characterizing the mechanisms of the anti-tumor effect of FH535 on pancreatic cancer cells.

Western blotting revealed that FH535 did not affect β-catenin expression in BxPC-3 cells. Interestingly, FH535 downregulated the protein level of total β-catenin in the PANC-1 cells, which differed from the results of most previous studies.[@b10-ott-8-1651] This cell type--dependent downregulation of β-catenin could have been due to the stabilization of axin, which suppresses β-catenin.[@b11-ott-8-1651] Axin is characterized as a tumor-suppressor gene, and it plays a key role in inhibiting the canonical Wnt pathway by forming molecular complexes with other proteins such as GSK-3β and adenomatous polyposis coli (APC).[@b38-ott-8-1651] Whether or not β-catenin expression was inhibited, the luciferase reporter assay proved that transcriptional activity of β-catenin pathway was decreased, which was consistent with previous study findings.[@b10-ott-8-1651]

Metastasis, the leading cause of cancer-related death, is a complex process comprising several steps, all of which we found were affected by FH535. First, FH535 inhibited pancreatic cancer cell migration. Microarray analyses revealed that FH535 altered the expression of several migration-related genes, which participate in focal adhesion, adhesion junctions, tight junctions, and/or motility regulation. Among these genes, the focal adhesion--related gene *PTEN*, considered "the most highly mutated tumor-suppressor gene in the post-p53 era",[@b39-ott-8-1651] plays a role in controlling cell migration.[@b40-ott-8-1651] The loss of PTEN protein expression or function has been reported in many human cancers, including ovarian, endometrial, and prostate carcinoma; breast cancer; and primary gastrointestinal stromal tumor.[@b41-ott-8-1651],[@b42-ott-8-1651] We also found that FH535 downregulated the adhesion junction--related gene *TLN1*, which encodes a cytoskeletal protein that is concentrated in areas of cell--substratum and cell--cell contact. The encoded protein plays a significant role in actin filament assembly and in the spread and migration of various cell types.[@b43-ott-8-1651],[@b44-ott-8-1651] TLN1 is codistributed with integrins in the cell surface membrane, aiding the attachment of adherent cells to extracellular matrices and lymphocytes to other cells. In our study, tight junction protein 1 (TJP1), which plays a critical role in cell--cell interaction, proliferation, and differentiation, was upregulated. TJP1 is an important marker of tight junction integrity, which is disrupted in many highly invasive cancers; upregulated TJP1 correlates with favorable survival in breast cancer and gastrointestinal stromal tumor.[@b45-ott-8-1651],[@b46-ott-8-1651] The motility-related gene *VEGFA* significantly increases the motility of pancreatic cancer cells. The vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) inhibitors bevacizumab and sunitinib significantly decrease pancreatic cancer cell motility.[@b47-ott-8-1651] In our study, FH535 not only suppressed *VEGFA* expression but also inhibited cell motility, suggesting the involvement of a similar mechanism.

To establish metastasis, tumor cells must traverse the basement membrane to reach the connective tissues. Accordingly, we investigated the anti-invasive effect of FH535. The Transwell assay proved that FH535 inhibited invasion. In vitro invasion can be divided into several steps, including matrix adhesion, matrix degradation, and EMT. We analyzed the expression of the genes involved in these steps using microarray and found that FH535 significantly downregulated the cell adhesion molecule ITGA5; *ITGA5* knockdown results in decreased adhesion in pancreatic cancer cells.[@b48-ott-8-1651] The ability of matrix metalloproteinases (MMPs) to degrade extracellular matrix proteins has been well characterized; therefore, they have been studied extensively to elucidate their involvement in both tumor development and progression. Different MMPs play different roles in tumorigenesis. MMP15 appears to be upregulated during colorectal tumorigenesis, and past research has shown stromal localization of MMP15 in the early phases of neoplastic transformation in colorectal cancer.[@b49-ott-8-1651] In our study, FH535 downregulated MMP15. Epithelial cells are characterized by well-developed junctions and apical--basolateral polarization; on the contrary, mesenchymal cells lack polarization due to the loss of an organized junctional layer. Cell metastasis is correlated with EMT. In the present study, FH535 downregulated Snail, which is upregulated during EMT.[@b50-ott-8-1651] In human colorectal cancer cells, overexpression of Snail induces not only EMT but also a cancer stem cell--like phenotype, which enhances cell migration and invasion in vitro and increases metastasis formation in vivo.[@b51-ott-8-1651] Snail also plays an essential role in human pancreatic cancer progression and metastasis.[@b52-ott-8-1651],[@b53-ott-8-1651] In the clinical setting, overexpression of Snail was previously associated with poorer prognosis and a more invasive phenotype in many malignancies.[@b54-ott-8-1651]--[@b56-ott-8-1651] We also detected the downregulation of TGFB1, a classic EMT stimulator.[@b57-ott-8-1651] TGFB1 overexpression is associated with early recurrence following resection and decreased survival;[@b58-ott-8-1651] consistent with our study, the suppression of TGFB1 activity in immune-deficient orthotopic mouse models of pancreatic cancer attenuated tumor growth and metastasis.[@b59-ott-8-1651],[@b60-ott-8-1651]

Besides metastasis, FH535 also induced G2/M arrest and inhibited pancreatic cancer cell proliferation. FH535 significantly upregulated the G2/M regulator gene *BCCIP* while downregulating the cell cycle regulatory genes *CCNG1* and *SERTAD1*. Human BCCIP, a protein that interacts with BRCA2 and CDKN1A (Cip1, p21), has been implicated in many cellular processes, including cell cycle regulation, DNA recombination and damage repair, telomere maintenance, embryonic development, and genomic stability.[@b61-ott-8-1651]--[@b63-ott-8-1651] *BCCIP* knockdown and concomitant p53 deletion causes rapid development of medulloblastomas, which have a wide spectrum of alterations involving the Sonic hedgehog pathway, consistent with the caretaker responsibility of BCCIP in genomic integrity.[@b64-ott-8-1651] *BCCIP* expression is downregulated in human ovarian cancer, renal cell carcinoma, and colorectal cancer tissues, suggesting that the gene plays a role in the pathogenesis of these cancers.[@b63-ott-8-1651] The positive expression rate and intensity of CCNG1 in gastric carcinoma is significantly correlated with tumor differentiation. Elevated amounts of CCNG1 are frequently detected in malignant tissue tumors, including astrocytoma; melanoma; carcinoma of the esophagus, lung, and breast; and cancer of the cervix, uterus, and ovary.[@b65-ott-8-1651] It plays a pivotal role in hepatocellular carcinoma metastasis and may be a novel prognostic biomarker and therapeutic target.[@b66-ott-8-1651] SERTAD1 is involved in positive regulation of the cell cycle and proliferation;[@b67-ott-8-1651],[@b68-ott-8-1651] accordingly, its expression is upregulated in several tumor types.[@b69-ott-8-1651],[@b70-ott-8-1651] Studies indicate that SERTAD1 promotes proliferation by binding to the transcription factor E2F1 and by enhancing its transcriptional activity.[@b71-ott-8-1651] Experimental overexpression of SERTAD1 provoked hyperproliferation,[@b72-ott-8-1651] genomic instability,[@b68-ott-8-1651] and inhibition of apoptosis.[@b73-ott-8-1651]

We demonstrated that FH535 significantly inhibits pancreatic cancer cell metastasis by suppressing migration, invasion, and adhesion and induces the accumulation of cells in the G2/M phase to suppress proliferation. These results suggest that FH535 is a potential candidate for pancreatic cancer treatment. Some of the identified genes that responded to FH535 are well-established direct targets of the Wnt/β-catenin pathway. However, it has not been proven that the other identified genes are located downstream of the pathway. FH535 might affect the expression of these genes through the Wnt/β-catenin pathway indirectly or in a β-catenin independent manner. In fact, FH535 not only antagonizes β-catenin/TCF-mediated transcription but also inhibits recruitment of the coactivators glucocorticoid receptor-interacting protein 1 (GRIP1) and β-catenin to peroxisome proliferator-activated receptor (PPAR)δ and PPARγ,[@b10-ott-8-1651] suggesting that these mechanisms could also be involved in the anti-cancer effect of FH535.
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FH535 suppressed the Wnt/β-catenin pathway in pancreatic cancer cells.

**Notes:** (**A**) Time-dependent decrease by FH535 of nuclear and total β-catenin protein levels in PANC-1 cells; FH535 did not affect nuclear or total β-catenin expression in BxPC-3 cells. (**B**) Dose-dependent decrease by FH535 of TCF-dependent transcription. \*\**P*\<0.01, significant differences vs the respective control groups. (**C**) Microarray analysis of expression regulation of genes downstream of the Wnt/β-catenin pathway upon 20 μM FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold.

**Abbreviations:** TCF, T-cell factor; h, hours.
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FH535 inhibited pancreatic cancer cell migration.

**Notes:** (**A**) Time-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell migration. \*\**P*\<0.01, significant differences vs the respective control groups. Microarray analysis of (**B**) focal adhesion--related, (**C**) adhesion junction--related, (**D**) tight junction--related, and (**E**) cell motility--related gene expression regulation upon FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/β-catenin pathway.

**Abbreviation:** h, hours.
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FH535 inhibited pancreatic cancer cell invasion.

**Notes:** (**A**) Dose-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell invasion. (**B**) Microarray analysis of extracellular matrix degradation--related gene expression regulation upon FH535 treatment. (**C**) Dose-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell adhesion. \**P*\<0.05, \*\**P*\<0.01, significant differences vs the respective control groups. (**D**) Microarray analysis of adhesion molecule--related gene expression regulation upon FH535 treatment. (**E**) Microarray analysis of EMT-related gene expression regulation upon FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/β-catenin pathway.

**Abbreviation:** EMT, epithelial--mesenchymal transition.
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###### 

Inhibitory effect of FH535 on pancreatic cancer cell growth.

**Notes:** (**A**) Dose- and time-dependent inhibition by FH535 of PANC-1 and BxPC-3 cell growth. (**B**) Dose-dependent inhibition by FH535 of the clone formation ability of BxPC-3 cells. *\*P*\<0.05, *\*\*P*\<0.01, significant differences vs the respective control groups. (**C**) Significant dose-dependent G2/M arrest following FH535 treatment in BxPC-3 cells. (**D**) Microarray analysis of cell cycle--related gene expression regulation upon 20 μM FH535 treatment. Up and down arrows indicate gene expression significantly upregulated or downregulated, respectively, by twofold. Asterisks indicate genes downstream of the Wnt/β-catenin pathway.

**Abbreviation:** h, hours.
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Microarray analysis of expression regulation of genes downstream of the Wnt/β-catenin pathway upon 20 μM FH535 treatment

  Gene          ID       Normalized intensity   
  ------------- -------- ---------------------- ------------
  *MYC*         4609     16.268158              15.204586
  *KRT18*       3875     15.975001              16.022995
  *PTTG1*       9232     15.680945              15.73604
  *ANGPTL4*     51129    15.190848              15.278334
  *KRT81*       3887     15.0413                14.423697
  *CD44*        960      15.006962              16.199093
  *PFDN5*       5204     14.879261              14.964103
  *KRT10*       3858     14.799751              13.889791
  *PTTG2*       10744    14.772796              14.547727
  *BIRC5*       332      14.757564              14.219355
  *PTTG1IP*     754      14.684395              14.533192
  *VEGFB*       7423     14.498004              13.671163
  *CYR61*       3491     14.279853              14.790296
  *UBXN1*       51035    14.231482              14.049252
  *KRT7*        3855     14.184294              13.285099
  *WISP2*       8839     13.732449              12.493675
  *SOX9*        6662     13.574989              13.415171
  *EN2*         2020     13.393019              12.721889
  *JAG1*        182      12.427784              12.687155
  *FOSL1*       8061     12.344017              11.102832
  *MYCBP*       26292    12.284651              11.974781
  *SNAI1*       6615     12.28132               10.385736
  *KRT73*       319101   12.23975               11.053284
  *GJA1*        2697     12.226766              13.521647
  *IRX3*        79191    12.224495              12.16053
  *TBX1*        6899     12.181493              12.043698
  *DKK3*        27122    12.076692              10.961267
  *JUN*         3725     12.038464              12.673436
  *MSL1*        339287   11.920114              11.438548
  *KRT80*       144501   11.87818               12.039767
  *CCND3*       896      11.576098              10.075832
  *CDKN2A*      1029     11.343829              11.097562
  *EFNB1*       1947     11.337793              10.368351
  *PTTG3P*      26255    11.33311               10.750982
  *KRT83*       3889     11.319811              9.89329
  *KRT19*       3880     11.289505              11.101922
  *CEBPD*       1052     11.196305              10.068165
  *PPARD*       5467     11.19087               10.731722
  *ANTXR1*      84168    11.149265              12.122571
  *EGFR*        1956     11.122326              12.333595
  *CDX4*        1046     10.933424              9.588729
  *ISLR*        3671     10.854443              9.725897
  *TWIST2*      117581   10.853075              10.129753
  *VEGFA*       7422     10.833399              10.087871
  *CTGF*        1490     10.809845              11.98555
  *FZD7*        8324     10.711324              9.901575
  *KRT85*       3891     10.621079              9.606193
  *CCND1*       595      10.543621              10.14267
  *TLE1*        7088     10.343489              9.271956
  *CDX1*        1044     10.329419              9.136879
  *KRT8*        3856     10.267347              8.319682
  *NRP1*        8829     10.246916              9.627893
  *DKK1*        22943    10.211538              10.979951
  *IRS1*        3667     10.175792              10.3609915
  *MMP2*        4313     10.153262              9.412593
  *IKBKG*       8517     10.132635              9.295626
  *TIAM1*       7074     10.117085              11.627998
  *EGR1*        1958     10.007974              8.180263
  *MET*         4233     9.986441               12.74971
  *BGLAP*       632      9.971276               9.414629
  *VEGFC*       7424     9.923567               10.21814
  *AHR*         196      9.886938               11.936481
  *CACNA1G*     8913     9.812038               8.560494
  *KRT15*       3866     9.7214575              8.709181
  *PPAP2B*      8613     9.718731               9.956581
  *KRT86*       3892     9.707824               9.012362
  *KRT23*       25984    9.573925               7.977122
  *GBX2*        2637     9.409858               9.626151
  *KRT39*       390792   9.284486               7.929165
  *WNT3A*       89780    9.275467               8.68014
  *PLAUR*       5329     9.265003               8.37788
  *ID2*         3398     9.226584               8.999163
  *MAEA*        10296    9.087043               8.91366
  *DAB2*        1601     9.034534               10.517419
  *ETS2*        2114     8.999426               10.445461
  *KRT31*       3881     8.998071               7.96933
  *TNFRSF11A*   8792     8.943393               9.029845
  *RET*         5979     8.9224615              7.809108
  *UBXN6*       80700    8.850218               7.6966906
  *STRA6*       64220    8.746183               7.1663184
  *KLF5*        688      8.6543455              8.714795
  *KRT4*        3851     8.640165               7.6698284
  *UBXN4*       23190    8.607909               10.505396
  *LEF1*        51176    8.601926               9.380911
  *KRT76*       51350    8.571253               7.397269
  *UBXN2B*      137886   8.2286415              9.982969
  *UBXN11*      91544    8.179481               7.272692
  *LRP1*        4035     8.175423               6.988433
  *UBXN2A*      165324   8.133479               7.9562063
  *KRT9*        3857     8.110517               7.0731263
  *EDA*         1896     8.09645                7.4072337
  *KRT32*       3882     8.087603               7.7537346
  *FGF4*        2249     7.9492774              6.5977035
  *KRT3*        3850     7.8908534              8.469248
  *UBXN8*       7993     7.86574                9.013798
  *SIX1*        6495     7.818405               7.9264607
  *FOXN1*       8456     7.7998743              6.8640747
  *ETV6*        2120     7.7085342              7.0067773
  *KRT1*        3848     7.5221066              6.7497764
  *IL8*         3576     7.501872               6.6113296
  *NTRK2*       4915     7.497469               7.1365094
  *RUNX2*       860      7.4688272              8.628798
  *MMP11*       4320     7.460847               7.2920337
  *CDH1*        999      7.3595057              7.319695
  *TCF7L2*      6934     7.3556123              8.6040535
  *KRT78*       196374   7.349466               6.8676143
  *TCF7*        6932     7.270456               7.664296
  *SMO*         6608     7.222788               7.0400887
  *EFNB2*       1948     7.1960526              7.26771
  *CLDN1*       9076     7.1643777              8.943991
  *KRT33A*      3883     7.121948               6.808277
  *VCAN*        1462     7.045421               6.763195
  *MMP9*        4318     7.0101504              6.7540355
  *DLL1*        28514    6.969655               6.5782347
  *KRT13*       3860     6.949356               5.971072
  *IGF2*        3481     6.933426               6.170534
  *KRT26*       353288   6.869997               6.697632
  *TNFRSF9*     3604     6.862919               6.6031585
  *KRT74*       121391   6.778076               6.538765
  *TWIST1*      7291     6.765423               6.105777
  *NRCAM*       4897     6.677019               6.7818675
  *FGF9*        2254     6.6647215              5.7855196
  *TNFRSF11B*   4982     6.6092443              6.618697
  *CHL1*        10752    6.6082654              6.3569694
  *KRT34*       3885     6.601664               6.199431
  *KRT6A*       3853     6.536037               5.9656916
  *EDN1*        1906     6.476451               6.7537594
  *NOS2*        4843     6.425461               6.333558
  *GDF5*        8200     6.3569694              6.3291264
  *CCND2*       894      6.3239446              5.996339
  *DLK1*        8788     6.2332454              6.884508
  *KRT37*       8688     5.971611               5.881136
  *IL6*         3569     5.7313643              5.9466343
  *SOX2*        6657     5.6166873              6.7975965
  *TGFB3*       7043     5.5891886              6.0552535
  *KRT35*       3886     5.5883365              6.3580856
  *PTGS2*       5743     5.5262737              7.601541
  *BTRC*        8945     5.3152456              7.7473273

###### 

Microarray analysis of focal adhesion--related gene expression regulation upon FH535 treatment

  Gene         ID      Normalized intensity   
  ------------ ------- ---------------------- -----------
  *RPSA*       3921    16.551584              16.069508
  *RHOA*       387     15.761177              14.786651
  *ACTN4*      81      15.032014              14.01403
  *CAPN2*      824     14.947017              15.841314
  *RAC1*       5879    14.251518              15.113209
  *FLNA*       2316    14.083586              13.488903
  *FLNB*       2317    13.958575              13.296808
  *ITGB5*      3693    13.888797              13.484464
  *DNM1*       1759    13.640091              12.518821
  *TMEM132A*   54972   13.622586              13.150153
  *RAP1A*      5906    13.5597315             14.039375
  *HGS*        9146    13.533683              13.846248
  *VCL*        7414    13.376745              13.681126
  *DIAPH1*     1729    13.16062               13.659487
  *GNG11*      2791    13.022779              13.403848
  *AKT1*       207     12.957863              12.259176
  *RAC2*       5880    12.955015              11.604415
  *ITGA3*      3675    12.797894              12.391577
  *ITGB1*      3688    12.738785              13.636554
  *CAV1*       857     12.61244               13.617725
  *ITGB2*      3689    12.546266              11.473748
  *ACTN1*      87      12.409878              11.967234
  *ITGAV*      3685    12.278682              14.3424
  *ITGA6*      3655    12.273888              14.392418
  *ITGA5*      3678    12.169847              10.866323
  *ILK*        3611    12.11682               11.583433
  *TLN1*       7094    12.096641              10.645829
  *SGCE*       8910    12.047686              12.282321
  *ITGB4*      3691    11.982763              11.56935
  *PRKCA*      5578    11.918201              13.803304
  *CTNNB1*     1499    11.900537              11.841962
  *FXYD5*      53827   11.859393              10.980669
  *AKT2*       208     11.791592              10.995004
  *CAV2*       858     11.534644              11.731664
  *VAV2*       7410    11.322939              10.17948
  *CDC42*      998     11.250544              11.791042
  *PARVB*      29780   11.224628              9.830263
  *ZYX*        7791    10.997072              9.663998
  *VASP*       7408    10.877319              10.418066
  *RAF1*       5894    10.594473              10.865986
  *SHC1*       6464    10.287678              8.595637
  *DSP*        1832    10.226259              11.500326
  *PARVA*      55742   10.0804615             10.301352
  *ITGAM*      3684    10.003317              8.889115
  *AKT3*       10000   9.999831               12.071189
  *HRAS*       3265    9.972342               9.272375
  *PDPK1*      5170    9.005413               9.698432
  *HPSE*       10855   8.978405               8.067395
  *PTK2*       5747    8.939062               10.820772
  *DNM2*       1785    8.613899               7.43392
  *SH3PXD2A*   9644    8.566784               9.949804
  *BCAR1*      9564    8.529809               7.7692404
  *ACTN2*      88      8.437073               7.474538
  *PARD6B*     84612   8.172608               9.636746
  *SOS1*       6654    7.9648976              7.5355105
  *DST*        667     7.7908773              11.245214
  *ITGA11*     22801   7.7725782              7.250522
  *ITGA9*      3680    7.725706               7.2797456
  *PIK3CA*     5290    7.546133               9.475706
  *CRK*        1398    7.5114365              8.404298
  *ITGA2B*     3674    7.474538               6.8249826
  *PXN*        5829    7.426979               6.493304
  *SPTB*       6710    7.143782               6.598218
  *PTEN*       5728    7.0376005              9.120998
  *CASK*       8573    6.554297               9.147331
  *ITGA2*      3673    6.538141               10.171594
  *SORBS1*     10580   6.5160394              7.080136
  *SELE*       6401    5.8820415              7.629673
  *ARHGAP5*    394     5.628543               7.9602804
  *ITGA1*      3672    5.3547735              7.6031985
  *ZEB2*       9839    5.2203803              6.942315

###### 

Microarray analysis of adhesion junction--related gene expression regulation upon FH535 treatment

  Gene        ID          Normalized intensity   
  ----------- ----------- ---------------------- ------------
  *PFN1*      5216        16.843973              16.144138
  *RHOA*      387         15.761177              14.786651
  *ACTN4*     81          15.032014              14.01403
  *CD44*      960         15.006962              16.199093
  *RAC1*      5879        14.251518              15.113209
  *CTNNA1*    1495        14.209974              14.654735
  *FLNA*      2316        14.083586              13.488903
  *MAPRE1*    22919       13.413141              13.8757925
  *DIAPH1*    1729        13.16062               13.659487
  *RAC2*      5880        12.955015              11.604415
  *CD99*      4267        12.8705635             12.11682
  *JUP*       3728        12.776809              12.098349
  *ACTN1*     87          12.409878              11.967234
  *CDH2*      1000        12.27524               13.657263
  *TLN1*      7094        12.096641              10.645829
  *IQGAP1*    8826        11.903805              15.008826
  *CTNNB1*    1499        11.900537              11.841962
  *PKP3*      11187       11.572304              11.483009
  *CAV2*      858         11.534644              11.731664
  *MGAT5*     4249        11.399225              12.44798
  *CSNK2A1*   1457        11.389523              10.994029
  *PLEK2*     26499       11.380254              12.049034
  *ANAPC1*    64682       11.330902              11.025982
  *NOTCH1*    4851        11.311136              10.345143
  *CDC42*     998         11.250544              11.791042
  *NOTCH2*    4853        11.125797              10.202223
  *WASL*      8976        10.930079              12.483249
  *DLG5*      9231        10.567565              11.019769
  *SRC*       6714        10.48147               9.648777
  *PAK4*      10298       10.446864              8.676079
  *VEGFA*     7422        10.250756              7.901348
  *ZEB1*      6935        10.177025              13.283847
  *JAM3*      83700       10.084784              9.556893
  *PVRL2*     5819        10.018614              8.147698
  *MET*       4233        9.986441               12.74971
  *CSNK2A2*   1459        9.960693               9.169151
  *PTPN1*     5770        9.82763                9.271097
  *PTK2B*     2185        9.636893               10.68203
  *DOCK1*     1793        9.48097                11.021774
  *MAPK1*     5594        9.240688               9.218932
  *ARHGEF7*   8874        9.037083               9.147919
  *CBLL1*     79872       9.0251875              9.311203
  *PKP2*      5318        9.022291               10.025781
  *BAIAP2*    10458       9.018734               8.004229
  *JAM2*      58494       8.789471               8.162707
  *CAV3*      859         8.535716               8.229119
  *ACTN2*     88          8.437073               7.474538
  *PKP1*      5317        8.423988               7.3570046
  *CDH3*      1001        8.389479               7.50349
  *CSF1*      1435        8.360545               7.4550886
  *TJP3*      27134       8.295799               7.207067
  *WASF1*     8936        8.178464               7.4462004
  *PVRL1*     5818        8.152037               7.283169
  *ESR1*      2099        8.048168               7.405365
  *OCLN*      100506658   8.036663               9.494983
  *PIP5K1C*   23396       7.9606485              7.254657
  *CTNND1*    1500        7.8659673              7.09317
  *MAP1B*     4131        7.7052383              10.589897
  *DSG2*      1829        7.513804               8.2605915
  *CDH1*      999         7.3595057              7.319695
  *ACTN3*     89          7.355976               6.6988516
  *VCAN*      1462        7.045421               6.763195
  *DLL1*      28514       6.969655               6.5782347
  *VPS13A*    23230       6.859817               10.562696
  *DSG4*      147409      6.608555               6.1116643
  *DSC2*      1824        6.3962626              7.24841
  *INADL*     10207       6.08029                8.808925
  *PNN*       5411        5.9342465              7.5790677
  *APC*       324         5.3153567              6.5241365
  *ITGA2*     3673        6.538141               10.171594
  *SORBS1*    10580       6.5160394              7.080136
  *SELE*      6401        5.8820415              7.629673
  *ARHGAP5*   394         5.628543               7.9602804
  *ITGA1*     3672        5.3547735              7.6031985
  *ZEB2*      9839        5.2203803              6.942315

###### 

Microarray analysis of tight junction--related gene expression regulation upon FH535 treatment

  Gene        ID       Normalized intensity   
  ----------- -------- ---------------------- ------------
  *RHOA*      387      15.761177              14.786651
  *CLDN4*     1364     15.11957               14.539507
  *ACTN4*     81       15.032014              14.01403
  *CD44*      960      15.006962              16.199093
  *CAPN2*     824      14.947017              15.841314
  *TIMP2*     7077     14.796619              14.858342
  *CFL1*      1072     14.710272              13.114106
  *CSNK2B*    1460     14.4039135             14.575101
  *RAC1*      5879     14.251518              15.113209
  *CTNNA1*    1495     14.209974              14.654735
  *MAPRE1*    22919    13.413141              13.8757925
  *ARHGDIA*   396      13.207352              11.634186
  *EZR*       7430     13.144885              12.566931
  *JAG1*      182      12.427784              12.687155
  *ACTN1*     87       12.409878              11.967234
  *TSPAN13*   27075    12.246902              11.379381
  *ILK*       3611     12.11682               11.583433
  *ICAM1*     3383     12.0056095             11.118488
  *CLDN7*     1366     11.972866              11.032687
  *MMP1*      4312     11.905035              12.887484
  *CTNNB1*    1499     11.900537              11.841962
  *COL16A1*   1307     11.647751              10.777789
  *CSNK2A1*   1457     11.389523              10.994029
  *ENAH*      55740    11.354481              13.398125
  *MLLT4*     4301     11.299263              13.275789
  *CDC42*     998      11.250544              11.791042
  *IGF1R*     3480     11.2369585             12.140446
  *CLDN19*    149461   11.222952              10.278006
  *CTGF*      1490     10.809845              11.98555
  *FZD7*      8324     10.711324              9.901575
  *MAPRE2*    10982    10.535324              11.375724
  *SVIL*      6840     10.304885              11.463148
  *CLDN2*     9075     10.221999              7.959734
  *THBS3*     7059     10.1687765             9.736564
  *LIMK1*     3984     10.151468              9.52237
  *MPP5*      64398    10.149654              12.064446
  *TIAM1*     7074     10.117085              11.627998
  *CGN*       57530    10.004088              9.987757
  *CSNK2A2*   1459     9.960693               9.169151
  *PRKCI*     5584     9.934886               11.633633
  *CRKL*      1399     9.737389               9.574368
  *TJAP1*     93643    9.66933                9.609078
  *CLDN12*    9069     9.506469               10.83943
  *TJP1*      7082     9.28694                12.134832
  *PARD6A*    50855    9.12321                8.362814
  *ARHGEF7*   8874     9.037083               9.147919
  *PDPK1*     5170     9.005413               9.698432
  *CDH5*      1003     8.708324               7.5856657
  *LMO7*      4008     8.558113               9.277104
  *SPTAN1*    6709     8.494044               7.7864056
  *ACTN2*     88       8.437073               7.474538
  *CLDN9*     9080     8.4181795              7.5940213
  *CSF1*      1435     8.360545               7.4550886
  *TJP2*      9414     8.343918               7.3491254
  *HAS1*      3036     8.124433               7.6573296
  *CLDN16*    10686    7.9999046              7.022292
  *AMOTL1*    154810   7.8963585              7.8100796
  *CRK*       1398     7.5114365              8.404298
  *ACTN3*     89       7.355976               6.6988516
  *PRKCG*     5582     7.321149               6.9112835
  *CLDN6*     9074     7.220466               6.6578355
  *CLDN1*     9076     7.1643777              8.943991
  *CLDN15*    24146    7.0927997              6.5795236
  *CLDN10*    9071     7.0557775              6.613464
  *PTEN*      5728     7.0376005              9.120998
  *SMAD2*     4087     6.9688606              9.496367
  *PARD3*     56288    6.94016                7.33421
  *CLEC3B*    7123     6.6491346              6.5587797
  *SPP1*      6696     6.37645                6.842924
  *MAGI1*     9223     6.3656254              7.168139
  *CTTN*      2017     6.2022476              6.6959023
  *ERBB3*     2065     6.178696               5.9926624

###### 

Microarray analysis of cell motility--related gene expression regulation upon FH535 treatment

  Gene         ID          Normalized intensity   
  ------------ ----------- ---------------------- ------------
  *VIM*        7431        18.111416              18.417988
  *PERP*       64065       17.034954              17.530819
  *MYH9*       4627        16.01196               15.906586
  *RHOA*       387         15.761177              14.786651
  *ACTN4*      81          15.032014              14.01403
  *TIMP2*      7077        14.796619              14.858342
  *MSN*        4478        14.751841              15.357616
  *CFL1*       1072        14.710272              13.114106
  *RAC1*       5879        14.251518              15.113209
  *RAP1B*      5908        14.023661              15.037672
  *TIMP1*      7076        13.919523              13.2338505
  *CDK4*       1019        13.87332               13.635977
  *RHOC*       389         13.521647              12.094296
  *LAMC1*      3915        13.492421              14.51922
  *VCL*        7414        13.376745              13.681126
  *ACTR3*      10096       13.228158              14.45616
  *DIAPH1*     1729        13.16062               13.659487
  *EZR*        7430        13.144885              12.566931
  *VAPA*       9218        13.089962              13.857084
  *AKT1*       207         12.957863              12.259176
  *RAC2*       5880        12.955015              11.604415
  *ACTR2*      10097       12.94824               13.651513
  *ITGB1*      3688        12.738785              13.636554
  *PRKCZ*      5590        12.597843              11.836956
  *ITGB2*      3689        12.546266              11.473748
  *ACTN1*      87          12.409878              11.967234
  *ILK*        3611        12.11682               11.583433
  *SGCE*       8910        12.047686              12.282321
  *ICAM1*      3383        12.0056095             11.118488
  *PPL*        5493        11.998627              11.51075
  *PRKCA*      5578        11.918201              13.803304
  *PPPDE2*     27351       11.624274              11.774211
  *ENAH*       55740       11.354481              13.398125
  *CDC42*      998         11.250544              11.791042
  *EGFR*       1956        11.122326              12.333595
  *WASL*       8976        10.930079              12.483249
  *CALD1*      800         10.921519              12.294691
  *STEAP1*     26872       10.895491              11.820029
  *TGFB1*      7040        10.7152                9.03388
  *CAMK2N1*    55450       10.587699              10.065469
  *RDX*        5962        10.522251              12.191257
  *MCAM*       4162        10.452353              9.462444
  *ARF6*       382         10.415711              11.52632
  *SVIL*       6840        10.304885              11.463148
  *RGS2*       5997        10.257294              9.80196
  *VEGFA*      7422        10.250756              7.901348
  *CAPN1*      823         10.239203              8.216266
  *F11R*       50848       10.234683              9.044022
  *RND3*       390         10.199277              12.088578
  *MMP2*       4313        10.153262              9.412593
  *WASF2*      10163       10.085579              8.826545
  *FAT1*       2195        9.970972               12.042841
  *RHOB*       388         9.965946               8.545685
  *RAPGEF1*    2889        9.903289               8.354535
  *RASA1*      5921        9.702747               11.502001
  *PTK2B*      2185        9.636893               10.68203
  *ROCK1*      6093        9.603488               11.484902
  *MYH10*      4628        9.5496025              11.096066
  *MMP15*      4324        9.533566               8.395943
  *DOCK1*      1793        9.48097                11.021774
  *PAK2*       5062        9.287464               10.61245
  *PLAUR*      5329        9.265003               8.37788
  *CDC27*      996         9.129515               11.077047
  *MST1R*      4486        9.085802               9.12538
  *BAIAP2*     10458       9.018734               8.004229
  *PTK2*       5747        8.939062               10.820772
  *STAT3*      6774        8.847785               7.9192953
  *ARHGEF2*    9181        8.798216               8.383045
  *PKP4*       8502        8.663319               9.734335
  *MARK2*      2011        8.612933               8.00314
  *PVRL3*      25945       8.582907               9.851074
  *BCAR1*      9564        8.529809               7.7692404
  *ARVCF*      421         8.524339               8.364944
  *SPTAN1*     6709        8.494044               7.7864056
  *TJP2*       9414        8.343918               7.3491254
  *HCLS1*      3059        8.263556               7.7210197
  *WASF1*      8936        8.178464               7.4462004
  *HAS1*       3036        8.124433               7.6573296
  *ADAMTS13*   11093       8.074093               8.375932
  *ESR1*       2099        8.048168               7.405365
  *OCLN*       100506658   8.036663               9.494983
  *WAS*        7454        7.9598556              7.412658
  *CTNND1*     1500        7.8659673              7.09317
  *DOCK4*      9732        7.829811               10.702755
  *CDSN*       1041        7.738298               7.3062844
  *MAP1B*      4131        7.7052383              10.589897
  *MMP11*      4320        7.460847               7.2920337
  *PXN*        5829        7.426979               6.493304
  *ACTN3*      89          7.355976               6.6988516
  *MTSS1*      9788        7.3144355              8.826939
  *VCAN*       1462        7.045421               6.763195
  *MMP9*       4318        7.0101504              6.7540355
  *VTN*        7448        6.8925853              6.3992944
  *EXOC2*      55770       6.8692775              8.335709
  *ECM1*       1893        6.8224096              7.0186477
  *TWIST1*     7291        6.765423               6.105777
  *ADAMTS1*    9510        6.670437               7.5566187
  *CASK*       8573        6.554297               9.147331
  *PLCG1*      5335        6.326862               6.175169
  *CTTN*       2017        6.2022476              6.6959023
  *FARP2*      9855        5.4352922              5.775334
  *CTNND2*     1501        5.4170265              5.9111185

###### 

Microarray analysis of extracellular matrix degradation--related gene expression regulation upon FH535 treatment

  Gene         ID      Normalized intensity   
  ------------ ------- ---------------------- ------------
  *TGFBI*      7045    16.09069               15.894443
  *TIMP2*      7077    14.796619              14.858342
  *TIMP1*      7076    13.919523              13.2338505
  *LAMC1*      3915    13.492421              14.51922
  *MMP1*       4312    11.905035              12.887484
  *COL16A1*    1307    11.647751              10.777789
  *COL5A1*     1289    11.607744              10.272581
  *COL6A1*     1291    11.396863              10.174638
  *LAMB1*      3912    10.813978              9.924841
  *CTGF*       1490    10.809845              11.98555
  *THBS3*      7059    10.1687765             9.736564
  *MMP2*       4313    10.153262              9.412593
  *COL4A2*     1284    9.866227               8.850218
  *THBS1*      7057    9.663341               9.193558
  *MMP15*      4324    9.533566               8.395943
  *SPARC*      6678    9.32407                8.289816
  *COL7A1*     1294    8.711706               7.6560946
  *LAMB3*      3914    8.550647               8.319239
  *HAS1*       3036    8.124433               7.6573296
  *ADAMTS13*   11093   8.074093               8.375932
  *SPG7*       6687    7.799603               7.3888316
  *MMP11*      4320    7.460847               7.2920337
  *COL12A1*    1303    7.404812               8.422412
  *COL14A1*    7373    7.3424816              6.805993
  *TNC*        3371    7.329479               6.564947
  *VCAN*       1462    7.045421               6.763195
  *MMP9*       4318    7.0101504              6.7540355
  *VTN*        7448    6.8925853              6.3992944
  *ECM1*       1893    6.8224096              7.0186477
  *ADAMTS1*    9510    6.670437               7.5566187
  *CLEC3B*     7123    6.6491346              6.5587797
  *SPP1*       6696    6.37645                6.842924
  *LAMA3*      3909    6.1783895              5.889333

###### 

Microarray analysis of adhesion molecule--related gene expression regulation upon FH535 treatment

  Gene         ID      Normalized intensity   
  ------------ ------- ---------------------- -----------
  *CD44*       960     15.006962              16.199093
  *ITGB5*      3693    13.888797              13.484464
  *LAMC1*      3915    13.492421              14.51922
  *LAMB1*      3912    12.817556              13.73472
  *ITGA3*      3675    12.797894              12.391577
  *ITGB1*      3688    12.738785              13.636554
  *ITGAV*      3685    12.278682              14.3424
  *ITGA6*      3655    12.273888              14.392418
  *ITGA5*      3678    12.169847              10.866323
  *SGCE*       8910    12.047686              12.282321
  *ICAM1*      3383    12.0056095             11.118488
  *ITGB4*      3691    11.982763              11.56935
  *CTNNB1*     1499    11.900537              11.841962
  *CTNNA1*     1495    11.841962              11.517105
  *COL16A1*    1307    11.647751              10.777789
  *COL5A1*     1289    11.607744              10.272581
  *COL6A1*     1291    11.396863              10.174638
  *CTGF*       1490    10.809845              11.98555
  *CTNND1*     1500    10.622252              11.350482
  *THBS3*      7059    10.1687765             9.736564
  *ITGAM*      3684    10.003317              8.889115
  *THBS1*      7057    9.663341               9.193558
  *ITGA7*      3679    9.627002               8.878363
  *MMP15*      4324    9.533566               8.395943
  *COL7A1*     1294    8.711706               7.6560946
  *LAMB3*      3914    8.550647               8.319239
  *HAS1*       3036    8.124433               7.6573296
  *ADAMTS13*   11093   8.074093               8.375932
  *SPG7*       6687    7.990712               6.850328
  *COL12A1*    1303    7.404812               8.422412
  *CDH1*       999     7.3595057              7.319695
  *COL14A1*    7373    7.3424816              6.805993
  *TNC*        3371    7.329479               6.564947
  *VCAN*       1462    7.045421               6.763195
  *VTN*        7448    6.8925853              6.3992944
  *CLEC3B*     7123    6.6491346              6.5587797
  *ITGB2*      3689    6.6435785              7.713477
  *ITGA2*      3673    6.538141               10.171594
  *SPP1*       6696    6.37645                6.842924
  *LAMA3*      3909    6.1783895              5.889333
  *SELE*       6401    5.8820415              7.629673
  *CTNND2*     1501    5.4170265              5.9111185
  *ITGA1*      3672    5.3547735              7.6031985

###### 

Microarray analysis of EMT-related gene expression regulation upon FH535 treatment

  Gene         ID       Normalized intensity   
  ------------ -------- ---------------------- ------------
  *VIM*        7431     18.111416              18.417988
  *TGFBI*      7045     16.09069               15.894443
  *NME1*       4830     15.692858              15.573043
  *IGFBP4*     3487     14.852157              13.246835
  *MSN*        4478     14.751841              15.357616
  *RAC1*       5879     14.251518              15.113209
  *KRT7*       3855     14.184294              13.285099
  *TIMP1*      7076     13.919523              13.2338505
  *COL5A2*     1290     13.175857              12.833253
  *TCF3*       6929     13.00084               12.29279
  *AKT1*       207      12.957863              12.259176
  *ITGB1*      3688     12.738785              13.636554
  *CAV1*       857      12.61244               13.617725
  *SNAI1*      6615     12.28132               10.385736
  *ITGA5*      3678     12.169847              10.866323
  *TLN1*       7094     12.096641              10.645829
  *SYMPK*      8189     11.942529              12.312602
  *CTNNB1*     1499     11.900537              11.841962
  *FXYD5*      53827    11.859393              10.980669
  *BMP7*       655      11.688513              10.938241
  *COL5A1*     1289     11.607744              10.272581
  *AHNAK*      79026    11.605762              10.785921
  *CAV2*       858      11.534644              11.731664
  *NOTCH3*     4854     11.523583              10.370972
  *TLN2*       83660    11.404076              10.886059
  *COL6A1*     1291     11.396863              10.174638
  *KRT19*      3880     11.289505              11.101922
  *IGF1R*      3480     11.2369585             12.140446
  *EGFR*       1956     11.122326              12.333595
  *FYN*        2534     10.966112              11.325876
  *WASL*       8976     10.930079              12.483249
  *CALD1*      800      10.921519              12.294691
  *LAMB1*      3912     10.813978              9.924841
  *TGFB1*      7040     10.7152                9.03388
  *FZD7*       8324     10.711324              9.901575
  *SERPINE1*   5054     10.639182              10.452353
  *GRB2*       2885     10.605613              9.416897
  *RDX*        5962     10.522251              12.191257
  *SVIL*       6840     10.304885              11.463148
  *PLEC*       5339     10.301559              9.204668
  *SHC1*       6464     10.287678              8.595637
  *RGS2*       5997     10.257294              9.80196
  *MMP2*       4313     10.153262              9.412593
  *SSX2IP*     117178   10.144432              11.167568
  *COL4A2*     1284     9.866227               8.850218
  *PPAP2B*     8613     9.718731               9.956581
  *THBS1*      7057     9.663341               9.193558
  *ESAM*       90952    9.472261               8.959825
  *NOTCH4*     4855     9.433491               9.707824
  *SPARC*      6678     9.32407                8.289816
  *VEZT*       55591    9.128493               11.195451
  *MST1R*      4486     9.085802               9.12538
  *STAT3*      6774     8.847785               7.9192953
  *ZAK*        51776    8.719432               11.337164
  *COL7A1*     1294     8.711706               7.6560946
  *SMURF1*     57154    8.629299               9.522539
  *LAMB3*      3914     8.550647               8.319239
  *TNS1*       7145     8.064375               7.5303655
  *SPG7*       6687     7.990712               6.850328
  *SOS1*       6654     7.9648976              7.5355105
  *WIPF1*      7456     7.8996034              7.0742846
  *BMP1*       649      7.73736                6.776738
  *FOXC2*      2303     7.5557323              6.690961
  *COL12A1*    1303     7.404812               8.422412
  *CDH1*       999      7.3595057              7.319695
  *COL14A1*    7373     7.3424816              6.805993
  *TNC*        3371     7.329479               6.564947
  *IL1RN*      3557     7.2758436              6.734858
  *SOX10*      6663     7.0939784              6.8492174
  *VCAN*       1462     7.045421               6.763195
  *PTEN*       5728     7.0376005              9.120998
  *MMP9*       4318     7.0101504              6.7540355
  *MPP6*       51678    6.9906545              8.912582
  *SYK*        6850     6.4246235              6.223468
  *SPP1*       6696     6.37645                6.842924
  *ERBB3*      2065     6.178696               5.9926624
  *LAMA3*      3909     6.1783895              5.889333
  *BMP2*       650      6.0141077              7.1390386
  *SOS2*       6655     5.6132765              8.797646
  *TGFB3*      7043     5.5891886              6.0552535

**Abbreviation:** EMT, epithelial--mesenchymal transition.

###### 

Microarray analysis of cell cycle--related gene expression regulation upon 20 μM FH535 treatment

  Gene         ID      Normalized intensity   
  ------------ ------- ---------------------- ------------
  *MYC*        4609    16.268158              15.204586
  *CKS2*       1164    15.878164              15.394571
  *RHOA*       387     15.761177              14.786651
  *BIRC5*      332     14.757564              14.219355
  *CCNB1*      891     14.478785              14.022737
  *CCNB2*      9133    14.019871              14.271269
  *KPNA2*      3838    13.950185              14.971469
  *CDK4*       1019    13.87332               13.635977
  *CDKN2D*     1032    13.839806              12.513427
  *GADD45A*    1647    13.765451              13.130958
  *CDKN1C*     1028    13.694702              12.537176
  *PCNA*       5111    13.611973              13.2414665
  *CKS1B*      1163    13.609195              12.845673
  *MCM3*       4172    13.580797              13.911951
  *PRC1*       9055    13.4114275             14.32471
  *MAD2L1*     4085    13.297964              12.867024
  *CDK1*       983     13.286596              13.600226
  *DDIT3*      1649    13.135856              11.871853
  *SERTAD1*    29950   13.060848              11.212
  *IGF2*       3481    13.0203                13.799717
  *AKT1*       207     12.957863              12.259176
  *GNL3*       26354   12.891848              14.223899
  *ITGB1*      3688    12.738785              13.636554
  *RASSF1*     11186   12.559567              11.458946
  *CDK7*       1022    12.553116              13.288865
  *CDC34*      997     12.53036               11.302476
  *TFDP2*      7029    12.527303              12.6644745
  *CDC20*      991     12.526335              11.232994
  *CDKN3*      1033    12.486179              12.966997
  *MAP2K1*     5604    12.483637              11.714967
  *CUL3*       8452    12.389215              13.715795
  *FOSL1*      8061    12.344017              11.102832
  *ILK*        3611    12.11682               11.583433
  *FOXO3*      2309    12.095011              13.865094
  *MNAT1*      4331    12.074865              12.456777
  *JUN*        3725    12.038464              12.673436
  *PDK2*       5164    11.944916              10.781894
  *CTNNB1*     1499    11.900537              11.841962
  *WEE1*       7465    11.894105              13.381722
  *MCM2*       4171    11.862871              11.269842
  *AURKB*      9212    11.800928              9.697033
  *PPP1R15A*   23645   11.676006              10.124018
  *MDC1*       9656    11.649198              10.940614
  *CDKN2C*     1031    11.6150875             11.096327
  *CCND3*      896     11.576098              10.075832
  *CCNE1*      898     11.407219              11.045229
  *CDKN2A*     1029    11.343829              11.097562
  *AURKA*      6790    11.181647              10.961699
  *RAD1*       5810    11.162613              9.890079
  *NOTCH2*     4853    11.125797              10.202223
  *EGFR*       1956    11.122326              12.333595
  *CDK5*       1020    11.117936              10.542482
  *RAD51*      5888    11.1082325             10.784544
  *CCNA2*      890     10.911861              10.9871645
  *MCM4*       4173    10.849212              11.05679
  *CDC16*      8881    10.808938              13.084003
  *BCCIP*      56647   10.778181              12.021907
  *CDC25C*     995     10.672214              10.564099
  *RB1*        5925    10.640414              12.741512
  *CCNC*       892     10.610059              10.50804
  *CDK9*       1025    10.606858              9.6394415
  *GRB2*       2885    10.605613              9.416897
  *ATM*        472     10.5960865             9.790577
  *PPM1D*      8493    10.580978              9.338833
  *CCND1*      595     10.543621              10.14267
  *PKD1*       5310    10.471296              9.29677
  *E2F3*       1871    10.412796              12.061844
  *CCNG1*      900     10.409301              9.063653
  *CDK5R1*     8851    10.322197              10.292204
  *PDK1*       5163    10.321034              10.933424
  *MAD2L2*     10459   10.306548              9.040705
  *SHC1*       6464    10.287678              8.595637
  *CCNT1*      904     10.17827               11.456285
  *CDK2*       1017    10.10528               9.357359
  *RUVBL1*     8607    10.000026              8.814938
  *SKP2*       6502    9.937107               8.872935
  *CASP3*      836     9.893856               10.658698
  *AHR*        196     9.886938               11.936481
  *RAD9A*      5883    9.855825               8.961951
  *PA2G4*      5036    9.737894               8.966842
  *CHEK2*      11200   9.726725               10.255492
  *INS*        3630    9.673779               8.813154
  *BBS4*       585     9.597437               9.65494
  *SIAH1*      6477    9.530121               9.295226
  *CCNG2*      901     9.4692955              8.337656
  *RBBP8*      5932    9.454372               12.631638
  *MAPK3*      5595    9.447224               7.818405
  *TFDP1*      7027    9.4434185              9.030092
  *E2F1*       1869    9.397123               8.754342
  *CDK5RAP2*   55755   9.390803               10.79269
  *MAPK1*      5594    9.240688               9.218932
  *MKI67*      4288    9.233824               8.092867
  *ID2*        3398    9.226584               8.999163
  *CUL1*       8454    9.221058               10.794849
  *RBL2*       5934    9.160267               10.348637
  *JAG2*       3714    9.075178               8.140677
  *GTSE1*      51512   9.04477                8.488665
  *CHEK1*      1111    9.04231                9.651725
  *E2F4*       1874    9.035055               8.016477
  *G0S2*       50486   9.032754               8.410861
  *SESN2*      83667   8.951754               8.138044
  *PTK2*       5747    8.939062               10.820772
  *CDC25A*     993     8.677163               8.042739
  *MDM2*       4193    8.622698               7.73673
  *CDK5RAP1*   51654   8.508385               6.9220624
  *AXIN1*      8312    8.351635               7.6164603
  *ATR*        545     8.152882               11.634625
  *MCM5*       4174    8.055058               7.4200873
  *CDKN1A*     1026    8.007444               6.7135
  *SOS1*       6654    7.9648976              7.5355105
  *CDKN1B*     1027    7.8906517              6.7354736
  *GML*        2765    7.8596773              6.9595275
  *TSC1*       7248    7.6562896              9.700143
  *BRCA1*      672     7.620017               10.24544
  *CUL2*       8453    7.566332               9.5496025
  *STMN1*      3925    7.5155845              6.8102884
  *CDK8*       1024    7.5133963              6.9160185
  *TERT*       7015    7.4070444              7.4882307
  *ABL1*       25      7.3099413              6.6226487
  *PTEN*       5728    7.0376005              9.120998
  *MDM4*       4194    6.996299               8.63818
  *HUS1*       3364    6.976554               7.3689637
  *RBL1*       5933    6.7265186              8.035306
  *CCND2*      894     6.3239446              5.996339
  *BMP2*       650     6.0141077              7.1390386
  *ATRIP*      84126   5.912352               6.682503
  *CDC6*       990     5.8019896              6.064807
  *SOX2*       6657    5.6166873              6.7975965
  *PTGS2*      5743    5.5262737              7.601541
  *APC*        324     5.3153567              6.5241365
  *BTRC*       8945    5.3152456              7.7473273

[^1]: These authors contributed equally to this work
